UBS raises Amneal Pharmaceuticals price target to $23

0 min read | Published on 16 Jul 2026, 12:42 AM |Updated on 16 Jul 2026, 12:42 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

UBS analyst Ashwani Verma maintains a Buy rating on Amneal Pharmaceuticals, raising the price target from $19 to $23.

*this image is generated using AI for illustrative purposes only.

UBS analyst Ashwani Verma has maintained a Buy rating on Amneal Pharmaceuticals and raised the price target to $23. The previous target was $19.

The revised target suggests increased confidence in the stock's performance potential.

What specific factors drove UBS to increase the price target by 21%?

How might this rating boost impact investor sentiment toward Amneal Pharmaceuticals?

What upcoming milestones could further validate the revised price target?

Read Next Article

Amneal Pharmaceuticals to report Q2FY26 results on July 30

1 min read | Published on 10 Jul 2026, 04:55 AM |Updated on 10 Jul 2026, 04:55 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Amneal Pharmaceuticals will release its Q2FY26 financial results on July 30, 2026, followed by an 8:30 a.m. ET webcast. Investors can access the event via the company's website or by phone using access code 901153095.

*this image is generated using AI for illustrative purposes only.

Amneal Pharmaceuticals will report its second quarter 2026 financial results on July 30, 2026, before market open. The announcement will provide insights into the company's performance for the quarter, with a live audio webcast scheduled for 8:30 a.m. ET to discuss the details. Investors and stakeholders can access the financial results and the live webcast through the Investor Relations section of Amneal's website at investors.amneal.com.

Access Details

To participate in the webcast, individuals must register in advance through the provided link on the company's website. For those preferring to join via phone, domestic participants in the U.S. can dial 1 (833) 461-5787, while international callers can access a list of toll-free numbers on the site. The access code required for the call is 901153095. A replay of the webcast will be made available shortly after the conclusion of the live event.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals is a global biopharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 2002 by co-CEOs Chirag and Chintu Patel, the company focuses on expanding access to affordable and innovative medicines. Its portfolio includes approximately 300 complex, specialty, and biosimilar medicines, with over 160 million prescriptions delivered annually, primarily in the United States. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE, catering to diverse healthcare needs.

What key performance indicators will investors focus on during Amneal's Q2 2026 earnings call?

How might Amneal's Specialty segment growth impact its overall financial performance in 2026?

What strategic initiatives could Amneal announce to expand its biosimilar portfolio post-Q2 2026?